INBIOGEN Co., Ltd. (KRX:101140)

INBIOGEN Statistics

Total Valuation

INBIOGEN has a market cap or net worth of KRW 88.76 billion. The enterprise value is 89.03 billion.

Market Cap	88.76B
Enterprise Value	89.03B

Important Dates

The last earnings date was Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

INBIOGEN has 9.98 million shares outstanding.

Current Share Class	9.98M
Shares Outstanding	9.98M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	n/a
Float	2.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.10
PB Ratio	0.56
P/TBV Ratio	0.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-62.76
EV / Sales	14.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.91

Financial Position

The company has a current ratio of 2.86, with a Debt / Equity ratio of 0.01.

Current Ratio	2.86
Quick Ratio	2.79
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.21
Interest Coverage	-55.23

Financial Efficiency

Return on equity (ROE) is -0.89% and return on invested capital (ROIC) is -2.64%.

Return on Equity (ROE)	-0.89%
Return on Assets (ROA)	-1.68%
Return on Invested Capital (ROIC)	-2.64%
Return on Capital Employed (ROCE)	-2.74%
Weighted Average Cost of Capital (WACC)	9.44%
Revenue Per Employee	153.58M
Profits Per Employee	-34.60M
Employee Count	41
Asset Turnover	0.04
Inventory Turnover	94.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +23.64% in the last 52 weeks. The beta is 0.95, so INBIOGEN's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	+23.64%
50-Day Moving Average	9,389.00
200-Day Moving Average	11,085.40
Relative Strength Index (RSI)	48.95
Average Volume (20 Days)	38,730

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, INBIOGEN had revenue of KRW 6.30 billion and -1.42 billion in losses.

Revenue	6.30B
Gross Profit	-384.38M
Operating Income	-4.33B
Pretax Income	-1.42B
Net Income	-1.42B
EBITDA	-3.97B
EBIT	-4.33B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 901.70 million in cash and 1.17 billion in debt, with a net cash position of -266.07 million or -26.65 per share.

Cash & Cash Equivalents	901.70M
Total Debt	1.17B
Net Cash	-266.07M
Net Cash Per Share	-26.65
Equity (Book Value)	157.64B
Book Value Per Share	n/a
Working Capital	3.46B

Cash Flow

In the last 12 months, operating cash flow was -5.55 billion and capital expenditures -42.50 million, giving a free cash flow of -5.60 billion.

Operating Cash Flow	-5.55B
Capital Expenditures	-42.50M
Depreciation & Amortization	363.49M
Net Borrowing	272.97M
Free Cash Flow	-5.60B
FCF Per Share	-560.51

Margins

Gross margin is -6.10%, with operating and profit margins of -68.81% and -22.53%.

Gross Margin	-6.10%
Operating Margin	-68.81%
Pretax Margin	-22.53%
Profit Margin	-22.53%
EBITDA Margin	-63.04%
EBIT Margin	-68.81%
FCF Margin	n/a

Dividends & Yields

INBIOGEN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1.60%
FCF Yield	-6.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 21, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Sep 21, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

INBIOGEN has an Altman Z-Score of 26.2.

Altman Z-Score	26.2
Piotroski F-Score	n/a